Vext Science (TSE:VEXT) has released an update.
Vext Science, Inc. has reported a revenue of $8.4 million and an adjusted EBITDA of $1.1 million for Q2 2024. Poised for growth with a significant footprint in Ohio, Vext anticipates a revenue surge following the state’s adult-use cannabis program launch. The company’s strong position in the market is supported by its comprehensive Ohio network, including cultivation, manufacturing facilities, and retail dispensaries.
For further insights into TSE:VEXT stock, check out TipRanks’ Stock Analysis page.
